Identification and human pharmacokinetics of dihydroergotoxine metabolites in man: preliminary results.

Article Details

Citation
Copy to clipboard

Bicalho B, Giolo JM, Lilla S, De Nucci G

Identification and human pharmacokinetics of dihydroergotoxine metabolites in man: preliminary results.

Biopharm Drug Dispos. 2008 Jan;29(1):17-28. doi: 10.1002/bdd.585.

PubMed ID
17941060 [ View in PubMed
]
Abstract

Dihydroergotoxine is a mixture of semi-synthetic ergot alkaloids mainly used for age-related cognitive impairment. In this study, dihydroergotoxine (30 microM) was added to incubates of rat and bovine liver microsomes, and the resulting major metabolites were identified as hydroxy-dihydroergocornine, hydroxy-dihydroergocryptine and hydroxy-dihydroergocristine on the basis of molecular mass measurements, determined with a time-of-flight mass spectrometer. The relevance of these to humans was then investigated by simultaneously monitoring dihydroergotoxine and its hydroxy-metabolites in human plasma by LC-MS/MS after oral dosing of dihydroergotoxine mesylate (27 mg) to a healthy volunteer (male, age 45, height 1.93 m, weight 103 kg). In this preliminary approach, the peaks (C(max)) of dihydroergocornine, dihydroergocryptine and dihydroergocristine were about 0.04 microg/l. The peaks (C(max)) of their hydroxy-metabolites were 0.98, 0.53 and 0.30 microg/l, respectively. In conclusion, in this preliminary approach it was found that hydroxy-dihydroergocornine, hydroxy-dihydroergocryptine and hydroxy-dihydroergocristine were one order of magnitude higher in concentration than their parents in human plasma.

DrugBank Data that Cites this Article

Drugs